NPI registry status
Active
2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1659488930 M.D.
Verify on CMS → Behrouz Salehian, M.D.
Endocrinology, Diabetes & Metabolism Physician in Duarte, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 7,871 in Endocrinology, Diabetes & Metabolism Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
5K
Medicare Part D claims · 460 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
66%
generic claims · 32% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
99.1/100
▲ 16 pts above national avg 83.1 · Exceptional
Industry payments
$180.83
15 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2023
What the federal data shows
Behrouz Salehian, M.D. reported a CMS MIPS final score of 99.1/100 - above the 83.1 national average - and filed 4,941 Medicare Part D claims in 2023.
- 99.1/100
- MIPS score · +16 vs avg
- 5K
- Part D claims, 2023
- 66%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Behrouz Salehian, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023, the federal quality measure
99 Top 9% higher than 91% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
Where Behrouz Salehian, M.D. sits
This provider among endocrinology, diabetes & metabolism physician peers
Across the 2,521 endocrinology, diabetes & metabolism physician providers who report both Medicare Part D prescribing and a MIPS quality score, Behrouz Salehian, M.D. writes more Part D claims than 79% of them and scores higher on MIPS quality than 92% - placing this provider in the high-volume, high-quality quadrant. Volume reflects patient-panel size and specialty, not quality; the two axes are independent.
Part D claim volume vs MIPS quality, by specialty percentile
Each dot is one endocrinology, diabetes & metabolism physician peer from a representative sample of 60; the gold marker is Behrouz Salehian, M.D.. Source: CMS Medicare Part D Prescriber data and the CMS Merit-based Incentive Payment System, 2023.
✓
Board certification likely (heuristic, not verified)
Behrouz Salehian, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Behrouz Salehian, M.D.?
High performer (top quartile)Primary specialty
Endocrinology, Diabetes & Metabolism Physician
Medicare Part D claims
4,941 87% vs specialty avg
MIPS final score
99.1/100 16 pts vs avg
Specialty distribution in California
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among California providers
Medicare quality performance, MIPS
Behrouz Salehian, M.D.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 99.1/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) - 99.1/100 vs national avg 83.1
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Behrouz Salehian, M.D. appears in the CMS NPPES registry as an Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 1500 DUARTE RD, Duarte, CA, 91010, with a listed phone of (626) 359-8111. NPI 1659488930 was issued on 08/24/2006.
Medicare Part D records for calendar year 2023 show 4,941 prescription claims written by this provider, covering 460 Medicare beneficiaries and totaling roughly $2.2 million in drug spend, split 32% brand-name and 66% generic by claim count. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 99.1/100 for the 2023 performance year (Quality 85.2), compared with the national average of 83.1.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,871 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline.
Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist, always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1659488930 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 08/24/2006 |
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
99.1275
Final Score
Avg: 83.1
85.2396
Quality
100
Promoting Interoperability
Reporting: Group practice
Hospital and facility affiliations
Facilities where Behrouz Salehian, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
City OF Hope Medical Foundation
Duarte, CA
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Behrouz Salehian, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$181
Largest payer
Abbott Laboratories
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Behrouz Salehian, M.D.. To verify Behrouz Salehian, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Above average
Behrouz Salehian, M.D. - brand share 32.0%
Endocrinology, Diabetes & Metabolism Physician average
32% brand-name claims vs 66% generic, on 4,941 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
4,941
Total Claims
$2.2M
Total Drug Cost
460
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 10,447
- Total Day Supply
- 308,906
- Brand vs Generic
- 32% brand / 66% generic
- Brand Drug Cost
- $2.1M
- Generic Drug Cost
- $153K
- Antibiotic Claims
- 36
Patient Demographics
- Average Patient Age
- 71.5 years
- Avg HCC Risk Score
- 2.37
- Gender Split
- 64% female / 36% male
- Age Distribution
- <65: 67, 65-74: 216, 75-84: 143, 85+: 34
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What Behrouz Salehian, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Levothyroxine Sodium
Levothyroxine Sodium
598 claims
- Ozempic
Ozempic
279 claims
- Rosuvastatin Calcium
Rosuvastatin Calcium
271 claims
- Losartan Potassium
Losartan Potassium
268 claims
- Metformin Hcl
Metformin Hcl
256 claims
- Atorvastatin Calcium 173
Atorvastatin Calcium
173 claims
- Glimepiride 134
Glimepiride
134 claims
- Liothyronine Sodium 118
Liothyronine Sodium
118 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 598 |
| Ozempic Semaglutide | 279 |
| Rosuvastatin Calcium | 271 |
| Losartan Potassium | 268 |
| Metformin Hcl | 256 |
| Atorvastatin Calcium | 173 |
| Glimepiride | 134 |
| Liothyronine Sodium | 118 |
| Amlodipine Besylate | 109 |
| Hydrocortisone | 101 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
More Endocrinology, Diabetes & Metabolism Physician in CA →
All providers in California →
Compare specialties →
Endocrinology, Diabetes & Metabolism Physician Overview
How Behrouz Salehian, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
7,871
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider
Behrouz Salehian, M.D.'s 4,941 claims are above the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Salehian.
Dr. Anita Abraham
M.D.
Stockton, CA
Dr. Sallie Adams
M.D.
Roseville, CA
Ananta Addala
Palo Alto, CA
Dr. Helen Adelberg
M.D.
Encino, CA
Dr. David Aftergood
MD
Beverly Hills, CA
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Before you book an appointment
Use this federal record as your verification checklist, not as a recommendation.
- Confirm the NPI record is current in the official CMS registry, providers update their own NPPES details, and moves can lag. Verify this NPI
- Check the active license and any disciplinary history with the California medical board, federal registration is not a license check. Credential verification guide
- Weigh a second option: compare this provider with a nearby Endocrinology, Diabetes & Metabolism Physician peer on Medicare volume and prescribing patterns. Compare providers
Medicare Part D and MIPS figures describe practice patterns in federal programs only, they are not quality ratings, and PlainDoctor does not rate, rank, or recommend providers.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
How to Find a Doctor
Step-by-step guide to choosing a provider
Verify Credentials
Check NPI, board certification & license status
Medical Specialties Explained
Who treats what and how specialties differ
Understanding Medicare Claims Data
What prescribing data reveals about a provider
In-Network vs Out-of-Network
How insurance networks affect your costs
Telehealth Guide
Virtual care options and coverage in 2026
Explore California
Frequently Asked Questions
What is Behrouz Salehian, M.D.'s specialty? ▼
Behrouz Salehian, M.D. specializes in Endocrinology, Diabetes & Metabolism Physician and practices in Duarte, California. Credentials: M.D..
How much does Behrouz Salehian, M.D. prescribe under Medicare Part D? ▼
In 2023, Behrouz Salehian, M.D. wrote 4,941 Medicare Part D claims totaling $2.2M in drug costs for 460 beneficiaries.
What is Behrouz Salehian, M.D.'s Medicare quality score? ▼
Behrouz Salehian, M.D. has a CMS MIPS Final Score of 99.1/100 (Quality: 85.2). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is Behrouz Salehian, M.D. located? ▼
Behrouz Salehian, M.D. is located at 1500 DUARTE RD, Duarte, CA, 91010. Phone: (626) 359-8111.
What is Behrouz Salehian, M.D.'s NPI number? ▼
Behrouz Salehian, M.D.'s National Provider Identifier (NPI) is 1659488930, issued on 08/24/2006.
Does Behrouz Salehian, M.D. prescribe more brand-name or generic drugs? ▼
Behrouz Salehian, M.D.'s prescribing is 32% brand-name and 66% generic drugs by claim count, with $2.1M in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
There are 7,871 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does Behrouz Salehian, M.D. prescribe most often? ▼
Based on 2023 Medicare Part D data, Behrouz Salehian, M.D.'s most frequently prescribed drugs include Levothyroxine Sodium, Ozempic, Rosuvastatin Calcium. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Behrouz Salehian, M.D. accept Medicare? ▼
Behrouz Salehian, M.D. appears in CMS Medicare data with 4,941 Part D claims and 460 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Behrouz Salehian, M.D.'s credentials? ▼
Behrouz Salehian, M.D.'s NPI is 1659488930 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) - 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.